ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Paris, Île-de-France, FRA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Paris, France and 51 other locations

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Paris, France and 173 other locations

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Villejuif, France and 47 other locations

single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...

Enrolling
Leukemia, Myeloid
Drug: CC-96191

Phase 1

Celgene
Celgene

Paris, France and 13 other locations

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

Phase 1, Phase 2

Incyte
Incyte

Paris, France and 31 other locations

WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with acute myeloid leukemia (AML) who are in morphol...

Enrolling
Acute Myeloid Leukemia
Drug: Cyclophosphamide-Fludarabine (Cy/Flu)
Drug: oNKord®

Phase 1, Phase 2

Glycostem Therapeutics

Villejuif, France and 9 other locations

safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia...

Enrolling
Chronic Myeloid Leukemia
Drug: Venetoclax

Phase 2

Groupe Francophone des Myelodysplasies

Paris, France and 18 other locations

positive measurable residual disease post-allogeneic hematopoietic stem cell transplantation (MRD+ post-aHSCT), can enhance the graft versus leukemia...

Enrolling
Acute Myeloid Leukemia
Drug: Azacitidine
Biological: Sabatolimab

Phase 1, Phase 2

Novartis
Novartis

Paris 10, France and 13 other locations

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Uproleselan
Drug: Placebo

Phase 3

GlycoMimetics

Paris, Île-de-France, France and 69 other locations

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...

Active, not recruiting
Acute Myeloid Leukemia
Drug: S65487 and azacitidine

Phase 1, Phase 2

Servier
Servier

Villejuif, France and 10 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems